BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 36135056)

  • 1. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
    Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
    Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
    Xu H; Wang W; Yin J; Song C; Li L; Sun Z
    Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
    Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
    World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The need for immunotherapy when neoadjuvant chemoradiotherapy achieves pathologic complete response in stage IIIB non-small cell lung cancer: a case report.
    Lv C; Zhao L; Zhu Y; Wang P; Sun Z
    Ann Palliat Med; 2021 Apr; 10(4):4965-4969. PubMed ID: 33966430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.
    Zeng L; Zhou Y; Zhang X; Xu Q; Zhou C; Zeng F; Jiang W; Wang Z; Deng L; Yang H; Liu L; Xiong Y; Zhang B; Yang N; Zhang Y
    Lung Cancer; 2023 Apr; 178():134-142. PubMed ID: 36858002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review.
    Mei T; Wang T; Lei C; Jiang D; Zhou Q
    Front Immunol; 2023; 14():1272450. PubMed ID: 38304254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 14. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy.
    Li L; Chen T; Lai H; Zhang A; Zhao X; Wu J; Hong H; Wu L; Lin S; Wang K; Zhang H; Fang C
    Medicine (Baltimore); 2022 Jun; 101(23):e29336. PubMed ID: 35687776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma.
    Peer M; Azzam S; Cyjon A; Katsnelson R; Hayat H; Bar I; Merimsky O
    Sci Rep; 2021 Oct; 11(1):20232. PubMed ID: 34642407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
    Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.